Calidi Biotherapeutics, Inc. (CLDI)
- Previous Close
0.4370 - Open
0.4439 - Bid 0.4021 x 900
- Ask 0.4096 x 800
- Day's Range
0.4000 - 0.4551 - 52 Week Range
0.3500 - 4.9000 - Volume
307,562 - Avg. Volume
434,276 - Market Cap (intraday)
12.717M - Beta (5Y Monthly) 1.20
- PE Ratio (TTM)
-- - EPS (TTM)
-2.9700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.25
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, and Phase 1, dose-escalation clinical trial for NNV1 in patients with newly diagnosed high-grade gliomas; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, which is in pre-clinical studies; CLD-301) for multiple indications in preclinical studies; and CLD-400 for certain lung cancer and metastatic solid tumors. The company also offers NeuroNova, an oncolytic virus platform; and SuperNova platform. Calidi Biotherapeutics, Inc. is headquartered in San Diego, California.
www.calidibio.comRecent News: CLDI
View More
Performance Overview: CLDI
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLDI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLDI
View MoreValuation Measures
Market Cap
13.89M
Enterprise Value
11.34M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
9.06
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-112.48%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-23.81M
Diluted EPS (ttm)
-2.9700
Balance Sheet and Cash Flow
Total Cash (mrq)
9.59M
Total Debt/Equity (mrq)
357.52%
Levered Free Cash Flow (ttm)
-11.21M